Kairos Pharma Reports Promising Interim Phase 2 Results for ENV-105 in Prostate Cancer
TL;DR
Kairos Pharma's ENV-105 shows 86% clinical benefit in prostate cancer trials, positioning the company as a leader in overcoming cancer treatment resistance.
ENV-105 targets CD105 protein to reverse drug resistance, combined with apalutamide in Phase 2 trials showing sustained progression-free survival in prostate cancer patients.
This therapy offers new hope for prostate cancer patients by potentially restoring treatment effectiveness and extending progression-free survival beyond current standards.
Kairos Pharma's innovative antibody targets a resistance protein, showing remarkable 86% clinical benefit in advanced prostate cancer patients during ongoing trials.
Found this article helpful?
Share it with your network and spread the knowledge!
The clinical-stage biopharmaceutical company presented findings at the European Society for Medical Oncology meeting in Berlin showing that 86% of patients treated with ENV-105 combined with apalutamide experienced clinical benefit. All responding patients remained progression-free for at least four months, with half maintaining this status beyond one year. The study also demonstrated significant biomarker response, with seven of nine evaluable patients experiencing PSA reductions. These results support the therapy's potential to restore hormone responsiveness in patients who have developed resistance to standard treatments.
The randomized trial, conducted in collaboration with Cedars-Sinai and partner institutions, continues to enroll patients to further evaluate safety and long-term efficacy. ENV-105 represents a novel approach to cancer treatment as an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer therapies. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy frequently results in resistance and disease relapse.
ENV-105 aims to reverse drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. Beyond the current prostate cancer trial, the compound is also being evaluated in a Phase 1 trial for lung cancer, addressing significant unmet medical needs in oncology. The positive interim results suggest potential for ENV-105 to become an important therapeutic option for patients with advanced prostate cancer who have limited treatment alternatives.
The ongoing study represents an important step in validating the CD105 targeting approach for overcoming treatment resistance in solid tumors. Additional information about the company and its development programs can be found at https://ibn.fm/1KEqw. As the trial continues to enroll patients, researchers will gather more comprehensive data on the therapy's safety profile and durability of response in this challenging patient population.
Curated from InvestorBrandNetwork (IBN)
